Boston Scientific Corporation$47.23BDX · NYSE
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $21.84B | $20.18B | $19.37B | $18.87B | $19.13B | $16.07B | $17.29B | $15.98B |
| Cost of Revenue | $11.91B | $11.05B | $11.20B | $10.39B | $10.50B | $9.28B | $9.00B | $8.71B |
| Gross Profit | — | — | — | — | — | $7.58B | $8.29B | $7.27B |
| Research & Development | $1.26B | $1.19B | $1.24B | $1.26B | $1.28B | $1.04B | $1.06B | $1.00B |
| Selling, General & Administrative | $5.28B | $4.86B | $4.72B | $4.71B | $4.72B | $4.18B | $4.33B | $4.02B |
| Operating Expenses | $19.26B | $17.78B | $17.26B | $16.59B | $16.88B | $15.16B | $15.53B | $14.47B |
| Operating Income | $2.58B | $2.40B | $2.11B | $2.28B | $2.25B | $912.00M | $1.76B | $1.51B |
| Interest Expense | $613.00M | $528.00M | $452.00M | $398.00M | $469.00M | $528.00M | $639.00M | $706.00M |
| Other Income / (Expense) | -$123.00M | -$28.00M | -$46.00M | -$117.00M | -$99.00M | $23.00M | $43.00M | $305.00M |
| Income Before Taxes | $1.88B | $2.00B | $1.66B | $1.78B | $1.69B | $414.00M | $1.18B | $1.17B |
| Provision for Income Taxes | $203.00M | $300.00M | $132.00M | $148.00M | $88.00M | $62.00M | -$57.00M | $862.00M |
| Net Income | $1.68B | $1.71B | $1.48B | $1.78B | $2.09B | $874.00M | $1.23B | $311.00M |
| Basic EPS | $5.83 | $5.88 | $4.97 | $5.93 | $6.92 | $2.75 | $4.01 | $0.62 |
| Diluted EPS | $5.82 | $5.86 | $4.94 | $5.88 | $6.85 | $2.71 | $3.94 | $0.60 |
| Basic Shares Outstanding | 287.65M | 289.76M | 286.28M | 285.00M | 289.29M | 278.97M | 269.94M | 258.35M |
| Diluted Shares Outstanding | 288.51M | 291.01M | 288.39M | 287.36M | 292.09M | 282.40M | 274.77M | 264.62M |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Sep 2026 | $12.53 | $12.00 | $12.65 | 7 | ↑0 ↓0 |
| Sep 2027 | $13.36 | $13.04 | $13.75 | 8 | ↑0 ↓1 |
| Sep 2028 | $13.97 | $13.61 | $14.21 | 3 | ↑0 ↓0 |
| Sep 2029 | $15.17 | $15.17 | $15.17 | 1 | ↑0 ↓0 |
